Role of the Natriuretic Peptide System in Normal Growth and Growth Disorders

The C-type natriuretic peptide (CNP) and its receptor (NPR-B) are recognized as important regulators of longitudinal growth. Animal models involving CNP or NPR-B genes (Nppc or Npr2) support the fundamental role of CNP/NPR-B for endochondral ossification. Studies with these animals allow the development of potential drug therapies for dwarfism. Polymorphisms in two genes related to the CNP pathway have been implicated in height variability in healthy individuals. Biallelic loss-of-function mutations in NPR-B gene (NPR2) cause acromesomelic dysplasia type Maroteux, a skeletal dysplasia with extremely short stature. Heterozygous mutations in NPR2 are responsible for nonsyndromic familial short stature. Conversely, heterozygous gain-of-function mutations in NPR2 cause tall stature, with a variable phenotype. A phase 2 multicenter and multinational trial is being developed to evaluate a CNP analog treatment for achondroplasia. Pediatricians and endocrinologists must be aware of growth disorders related to natriuretic peptides, although there is still much to be learned about its diagnostic and therapeutic use.

[1]  M. Volpe,et al.  Natriuretic peptides in cardiovascular diseases: current use and perspectives. , 2014, European heart journal.

[2]  T. Ogata,et al.  Identification and functional characterization of two novel NPR2 mutations in Japanese patients with short stature. , 2014, The Journal of clinical endocrinology and metabolism.

[3]  T. Cho,et al.  Overgrowth syndrome associated with a gain‐of‐function mutation of the natriuretic peptide receptor 2 (NPR2) gene , 2014, American Journal of Medical Genetics. Part A.

[4]  G. Guerra‐Júnior,et al.  The Sitting Height/Height Ratio for Age in Healthy and Short Individuals and Its Potential Role in Selecting Short Children for SHOX Analysis , 2013, Hormone Research in Paediatrics.

[5]  A. Verkerk,et al.  An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. , 2013, The Journal of clinical endocrinology and metabolism.

[6]  Gabriela A. Vasques,et al.  Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature. , 2013, The Journal of clinical endocrinology and metabolism.

[7]  Thomas W. Mühleisen,et al.  Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture , 2013, Nature Genetics.

[8]  M. Conti,et al.  A novel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux type. , 2013, Human molecular genetics.

[9]  A. Munnich,et al.  Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. , 2012, American Journal of Human Genetics.

[10]  H. Yoshikawa,et al.  An Overgrowth Disorder Associated with Excessive Production of cGMP Due to a Gain-of-Function Mutation of the Natriuretic Peptide Receptor 2 Gene , 2012, PloS one.

[11]  M. Hutchison.  BDNF alters ERK/p38 MAPK activity ratios to promote differentiation in growth plate chondrocytes. , 2012, Molecular endocrinology.

[12]  W. Ahmad,et al.  Novel mutations in natriuretic peptide receptor-2 gene underlie acromesomelic dysplasia, type maroteaux , 2012, BMC Medical Genetics.

[13]  Yuan Cheng,et al.  C-type natriuretic peptide stimulates ovarian follicle development. , 2012, Molecular endocrinology.

[14]  Tom R. Gaunt,et al.  Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. , 2011, American journal of human genetics.

[15]  K. Sugiura,et al.  Granulosa Cell Ligand NPPC and Its Receptor NPR2 Maintain Meiotic Arrest in Mouse Oocytes , 2010, Science.

[16]  Ayellet V. Segrè,et al.  Hundreds of variants clustered in genomic loci and biological pathways affect human height , 2010, Nature.

[17]  K. Nakao,et al.  Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice. , 2009, American journal of physiology. Endocrinology and metabolism.

[18]  Yurii S. Aulchenko,et al.  A genome-wide association study of northwestern Europeans involves the C-type natriuretic peptide signaling pathway in the etiology of human height variation , 2009, Human molecular genetics.

[19]  K. Nakao,et al.  Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. , 2009, Endocrinology.

[20]  Inês Barroso,et al.  Meta-Analysis of Genome-Wide Scans for Human Adult Stature Identifies Novel Loci and Associations with Measures of Skeletal Frame Size , 2009, PLoS genetics.

[21]  L. Al-Gazali,et al.  Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux. , 2008, Human molecular genetics.

[22]  Bjarni V. Halldórsson,et al.  Many sequence variants affecting diversity of adult human height , 2008, Nature Genetics.

[23]  N. Philip,et al.  A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype , 2007, Human mutation.

[24]  W. Wilcox,et al.  C-natriuretic peptide: an important regulator of cartilage. , 2007, Molecular genetics and metabolism.

[25]  Y. Kamei,et al.  Intact kinase homology domain of natriuretic peptide receptor-B is essential for skeletal development. , 2007, The Journal of clinical endocrinology and metabolism.

[26]  T. Tsuji,et al.  Short-limbed dwarfism: slw is a new allele of Npr2 causing chondrodysplasia. , 2007, The Journal of heredity.

[27]  R. Ravazzolo,et al.  Overexpression of the C‐type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation , 2007, Human mutation.

[28]  R. Serra,et al.  C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and – independent pathways , 2007, BMC Developmental Biology.

[29]  R. Olney.  C-type natriuretic peptide in growth: a new paradigm. , 2006, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[30]  M. Warman,et al.  Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. , 2006, The Journal of clinical endocrinology and metabolism.

[31]  D. Dickey,et al.  Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. , 2006, Endocrine reviews.

[32]  K. Nakao,et al.  Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. , 2005, Bone.

[33]  S. Schulz.  C-type natriuretic peptide and guanylyl cyclase B receptor , 2005, Peptides.

[34]  T. Tsuji,et al.  A Loss-of-Function Mutation in Natriuretic Peptide Receptor 2 (Npr2) Gene Is Responsible for Disproportionate Dwarfism in cn/cn Mouse* , 2005, Journal of Biological Chemistry.

[35]  R. Hammer,et al.  Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Mundlos,et al.  Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. , 2004, American journal of human genetics.

[37]  Jennifer R. Harris,et al.  Heritability of Adult Body Height: A Comparative Study of Twin Cohorts in Eight Countries , 2003, Twin Research.

[38]  K. Nakao,et al.  Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. , 2002, Endocrinology.

[39]  D. Holmes,et al.  Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. , 2002, Cardiovascular research.

[40]  K. Nakao,et al.  Dwarfism and early death in mice lacking C-type natriuretic peptide , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Jaubert,et al.  Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Yamauchi,et al.  The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  T. Chrisman,et al.  Reciprocal Antagonism Coordinates C-type Natriuretic Peptide and Mitogen-signaling Pathways in Fibroblasts* , 1999, The Journal of Biological Chemistry.

[44]  N. McNicoll,et al.  Glycosylation is critical for natriuretic peptide receptor-B function , 1996, Molecular and Cellular Biochemistry.

[45]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. , 1992, Journal of hypertension.

[46]  R. Marini,et al.  Acromesomelic dwarfism in a child with an interesting family history , 2005, Pediatric Radiology.

[47]  K. Nakao,et al.  Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway , 2004, Nature Medicine.

[48]  明宏 八十田.  Natriuretic peptide regulation of endochondral ossification : evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway , 1999 .

[49]  Vincent T.F. Yeung,et al.  Natriuretic Peptide Receptors , 1993 .

[50]  L. Langer,et al.  Acromesomelic dysplasia. , 1980, Radiology.

[51]  R. Pilz,et al.  Regulation of Gene Expression by Cyclic GMP , 2003, Circulation research.